Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

December 31, 2009

Conditions
Alzheimer's DiseaseAmnestic Mild Cognitive Impairment
Interventions
DRUG

AH110690 (18F) Injection

All subjects will receive an I.V. dose of \[18F\]AH110690 (less than 10 mg of total AH110690). The target activity of a single administration of \[18F\]AH110690 will be 185 MBq (equivalent to a dose of approximately 6 mSv).

Trial Locations (1)

Unknown

GE Healthcare, Oslo

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

i3 Statprobe

INDUSTRY

collaborator

Medpace, Inc.

INDUSTRY

collaborator

Hvidovre University Hospital

OTHER

lead

GE Healthcare

INDUSTRY

NCT00785759 - Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers | Biotech Hunter | Biotech Hunter